The most dangerous aisle in the convenience store is not the one with the beer.
It is the one behind the cashier, at eye level, next to the candy bars and the lottery tickets. Nicotine pouches. Vapes. Cigarettes. The packaging is sleek. The flavors are mango, mint, and cotton candy. The marketing is aspirational. And the molecule inside is a neurotoxin that was registered as an insecticide for centuries before it was ever marketed as a lifestyle product. The same chemical that kills aphids on tomato plants is sold to teenagers as a way to take the edge off. This is not an accident of history. It is a category error that has been deliberately cultivated by an industry that understood, from the beginning, that nicotine is not a stimulant you enjoy. It is a pesticide you become dependent on.
The Original Nicotine: A Pesticide, Not a Pastime
The tobacco plant was introduced to Europe in 1559. By 1690, tobacco dust and extracts were being used to repel or kill insects, and tobacco smoke was used for fumigation (Metribolone, n.d.). Tobacco was reintroduced as an insecticide in the United States in 1814 (Metribolone, n.d.). By the early twentieth century, nicotine was being sprayed on grapevines and fruit trees across France as a standard agricultural insecticide (NYT, 1913). It was sold as a concentrated aqueous solution—Black Leaf 40, a 40% nicotine sulfate solution—and used against aphids, thrips, and whiteflies on fruits, vegetables, and ornamentals (Metribolone, n.d.). It was also used to immobilize wild animals: cattle weighing up to 450 kg could be quickly restrained with up to 3 mg/kg doses delivered by projectile syringe (Metribolone, n.d.).
The mechanism was understood long before the pharmacology was mapped. Nicotine is a neurotoxin. It binds to nicotinic acetylcholine receptors and, at insecticidal doses, causes sustained depolarization, paralysis, and death. The same receptor that mediates nicotine’s addictive effects in humans is the receptor that kills insects. The difference is dose, delivery, and the fact that humans have a blood-brain barrier that insects do not. The molecule does not know it is being used for recreation. It only knows it is an agonist, and it does what agonists do.
The Neonicotinoid Connection
If nicotine is the grandfather of nicotine-based pesticides, the neonicotinoids are its synthetic descendants. Imidacloprid, the principal example, was developed in the 1980s and became the most important new class of synthetic insecticides of the past three decades (Selective Toxicity of Neonicotinoids, 2002). The mechanism is identical: they act as agonists at the insect nicotinic acetylcholine receptor (Selective Toxicity of Neonicotinoids, 2002). The difference is selectivity. The botanical insecticide nicotine acts at the same target “without the neonicotinoid level of effectiveness or safety” (Selective Toxicity of Neonicotinoids, 2002).
The neonicotinoids are “selectively toxic” because of a molecular trick. Whereas ionized nicotine binds at an anionic subsite in the mammalian nAChR, the negatively tipped “magic nitro or cyano” groups of the neonicotinoids interact with a unique subsite consisting of cationic amino acid residues in the insect nAChR (Selective Toxicity of Neonicotinoids, 2002). This is why imidacloprid kills bees and not humans at comparable doses. But the selectivity is not absolute. Neonicotinoids have been shown to act as agonists on mammalian cerebellar neurons (Nicotine-Like Effects of Neonicotinoids, 2012), and their environmental persistence has made them a global ecological crisis.
The neonicotinoid story is the nicotine story repeated at industrial scale. A neurotoxin designed to kill insects was deployed across millions of hectares, accumulated in soil and water, and contaminated the pollen and nectar of the very pollinators that agriculture depends on. Sublethal exposure impairs homing ability in honey bees by disrupting energy metabolism and endocrine regulation (Sub-lethal Neonicotinoid Exposure, 2025). It reduces sperm count in bumblebee males by 41% (Even Sublethal Insecticide Dose, 2025). It alters gut microbiota in pollinators, decomposers, and aquatic organisms, with consequences for pollination, plant health, and ecosystem resilience (Collateral Damage of Neonicotinoid Insecticides, 2025). The European Union banned outdoor use of imidacloprid because the risks were too great (Sub-lethal Neonicotinoid Exposure, 2025). The United States did not.
Nicotine the Stimulant: The Marketing of a Neurotoxin
Here is the sleight of hand. Nicotine is classified as a stimulant, and the industry has spent decades promoting it as a mild, socially acceptable pick-me-up—a cousin of caffeine, a harmless way to focus. The claim is that “nicotine itself is not a particularly hazardous drug” and is “something on a par with the effects you get from caffeine” (Royal College of Physicians, as cited in Simon Chapman, 2019). The Royal Society for Public Health has stated that nicotine is “no more harmful than caffeine” (Cato, 2025).
This is a lie, and the lie is measurable. Nicotine is not caffeine. Caffeine consumed within recommended amounts is not harmful to health (RSPH, 2022). Nicotine is highly addictive and can cause heart, lung, kidney, stomach, and bowel issues even when consumed on its own (RSPH, 2022). Nicotine speeds up the heart, constricts blood vessels, and raises blood pressure (SAMHSA, n.d.). It increases the risk of heart attack, damages the coronary arteries, and increases the risk of type 2 diabetes (Nicotine-Containing Products, 2025). In young people whose brains are still developing, the effects are even more concerning: memory impairment, attention deficits, mood and sleep disorders, decreased energy, and increased risk of multiple addictions (Nicotine-Containing Products, 2025).
The comparison to caffeine is not merely inaccurate. It is a marketing strategy. The industry needs a respectable frame for a molecule that has been used as an insecticide, a rodenticide, and an animal immobilizer. Caffeine provides that frame. If nicotine is just caffeine with a different delivery system, then the pouches, the vapes, the gums, and the lozenges are just coffee alternatives. The frame collapses under the first glance at the pharmacology. But the frame does not need to survive scrutiny. It only needs to survive long enough to recruit a new generation of users.
The Pouches and the Youth
The newest delivery system is the nicotine pouch—a small, white, flavored bag that sits under the lip and releases nicotine into the bloodstream. The World Health Organization has warned that nicotine pouch brands are targeting youth as sales surge, emphasizing that nicotine itself is highly addictive and harmful, particularly for children, adolescents, and young adults whose brains are still developing (WHO, 2026). Nicotine exposure during adolescence can affect brain development, including impacts on attention and learning, and can increase the likelihood of long-term dependence and future use of other nicotine and tobacco products (WHO, 2026).
The products are discreet. They are flavored. They are marketed on social media. They are sold next to the candy bars. And they are producing the exact outcomes the industry designed them to produce: a new generation of nicotine-dependent users who would never have smoked a cigarette but will happily place a mango-flavored pouch under their lip. The oral pathology is already being documented: white hyperkeratotic lesions, gum irritation, and mucosal changes that are precursors to more serious conditions (Pathology of Oral Nicotine Pouches, 2025). The long-term health effects are unknown, but the mechanism of harm is the same as it has always been: nicotine constricts blood vessels, raises blood pressure, and rewires the brain’s reward system to prioritize the next dose over everything else.
The Regulatory Landscape: Two Philosophies, One Molecule
The FDA: Content Caps and Premarket Authorization.
In January 2025, the FDA proposed a rule to cap nicotine levels in cigarettes and certain other combusted tobacco products at 0.7 milligrams per gram of tobacco—a 96% reduction from current levels (FDA, 2025). The goal is to reduce nicotine to “minimally or nonaddictive” levels (FDA, 2025). The American Association for Cancer Research has expressed support, noting that the policy could dramatically reduce smoking-related disease (AACR, 2025).
But the FDA operates a premarket authorization model. Every new tobacco product must be reviewed and authorized before it can be sold. The agency recently granted Modified Risk Tobacco Product orders to 20 ZYN nicotine pouch products, allowing them to claim that switching from cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The authorized claim applies only to smokers who completely replace cigarettes with the pouches, not to dual users. The FDA has formally recognized that different nicotine products present different levels of risk.
The proposed content cap, however, addresses only combusted products. It does not touch the pouches, the vapes, the lozenges, or the gums. It leaves the nicotine replacement therapy industry intact. And it leaves the philosophical foundation of nicotine use untouched: the assumption that nicotine is a legitimate stimulant that some people enjoy and that the goal is merely to reduce the harm of one delivery method.
The European Union: Fragmented Bans and a Directive Written for a Different Era.
The European Union has been running a parallel—and in some respects more aggressive—regulatory experiment, with results that expose a fundamental difference in approach. The EU’s primary instrument is the Tobacco Products Directive (TPD). Unlike the FDA’s product-by-product authorization model, the TPD is a harmonization directive that sets baseline rules across all 27 member states. The current version, Directive 2014/40/EU, restricts nicotine-containing e-liquids to a maximum concentration of 20 mg/mL. This is the EU’s version of a nicotine cap, but it is a concentration limit, not a content limit. The TPD regulates only the nicotine yield per cigarette under standardized smoking conditions. The FDA proposal targets the nicotine content of the tobacco itself. The EU has not attempted to regulate the nicotine content of tobacco, and there is no EU-wide rule governing nicotine pouches at all.
That gap is now the central battleground. Nicotine pouches were not contemplated when the TPD was drafted. They contain no tobacco, so they fall outside the directive’s scope entirely. The result is a patchwork. France banned nicotine pouches in February 2025. Belgium banned them in October 2023; the Netherlands followed with a retail ban in January 2025. Latvia set a maximum nicotine content of 4 mg per pouch in January 2025. Germany, Austria, and Luxembourg have also enacted bans. Sweden—the home of snus and the ancestral market for oral nicotine—has sent official letters to EU countries imposing bans, aiming to prevent pouches from meeting the same regulatory fate.
This fragmentation is not a bug. It is the predictable consequence of a directive that was written before the products existed. The European Commission has acknowledged the problem. In May 2026, it opened a call for evidence to rewrite the TPD. The evaluation that preceded the consultation found “the largest gaps” in “harmonised rules for novel nicotine products”. The Commission is expected to publish its legislative proposal in the fourth quarter of 2026.
Eight member states—the Netherlands, Belgium, Finland, France, Hungary, Latvia, Slovenia, and Spain—have written to the Health Commissioner demanding maximum nicotine limits, standardized products, plain packaging, and broad flavor restrictions across all authorized nicotine categories. They want the revised framework to allow individual countries to ban nicotine pouches and disposable e-cigarettes, and they want a ban on advertising including influencer and creator content. Their stated goal is a “smoke-free generation” by 2040. The European Cancer Organisation has gone further, calling for the revision to “close regulatory gaps for new and emerging products” through technology-neutral definitions and a mechanism allowing the Commission to respond quickly to market developments.
The EU is also moving on the tax front. In July 2025, the Commission proposed a revision to the Tobacco Taxation Directive that would extend the scope of minimum excise duties to cover e-cigarettes, heated tobacco, and nicotine pouches. The proposal aims to increase the EU’s minimum tax rate, address disparities between member states, and harmonize the taxation of new nicotine products. The revenue projection is over €11 billion annually.
The contrast between the two jurisdictions is stark. The FDA has formally recognized that different nicotine products present different levels of risk, and has created a pathway for authorizing reduced-risk claims. The EU has no equivalent of the MRTP pathway, no premarket authorization for nicotine pouches at the EU level, and a directive that does not cover the product. The European market for nicotine pouches is being shaped by national bans rather than EU-wide rules. A pouch that is legal in Sweden is illegal in France. A pouch with 14 mg of nicotine is legal in one country and banned in another. The free movement of goods within the single market—the EU’s foundational principle—is being tested by a product that the directive never anticipated and the Commission has not yet regulated. The revision now underway is the EU’s attempt to close that gap. Whether it succeeds will depend on whether the member states can agree on a framework that treats nicotine as a category of regulated substances rather than a collection of products that each require their own rule. The FDA has already decided that the category matters. The EU is still deciding whether the category exists.
The Case for Phase-Out
Nicotine is a pesticide. It was used as an insecticide for centuries. Its synthetic descendants are causing a global pollinator crisis. Its pharmacological mechanism is the same in insects and humans: it hijacks the nicotinic acetylcholine receptor. The fact that humans have a blood-brain barrier that allows the molecule to produce euphoria and dependence rather than paralysis does not change what the molecule is. It only changes the dose and the delivery system.
The nicotine replacement therapy industry has perpetuated the assumption that nicotine is a legitimate stimulant that some people enjoy and that the goal is merely to reduce the harm of one delivery method. A 2025 paper in Tobacco Induced Diseases argues that “prolonged use of NRT perpetuates nicotine addiction and leads to adverse effects on the cardiovascular system and oropharyngeal irritation” and that the industry-driven nicotine products marketed as safe alternatives “have significant health risks and undermine cessation efforts” (NRT for Tobacco Cessation, 2025). The same paper notes that NRT, although effective for tobacco cessation, “can perpetuate nicotine addiction” (NRT for Tobacco Cessation, 2025).
The phase-out should not be limited to cigarettes. It should be comprehensive. Nicotine should be available only as a short-term, supervised cessation aid, prescribed by a physician, with a defined endpoint and monitoring. It should not be sold in convenience stores. It should not be flavored. It should not be marketed to youth. It should not be available in pouches, vapes, or any other delivery system designed to make the molecule more palatable and more accessible. The goal is not harm reduction. The goal is abolition.
This is not a radical position. It is the position that follows from the pharmacology. Nicotine is a neurotoxin. It is a pesticide. It belongs in the shed, not behind the counter. The fact that it has been packaged in candy flavors and marketed to teenagers is not a feature of a free society. It is a failure of regulation, a triumph of industry lobbying, and a betrayal of the public health principles that have successfully reduced smoking rates for decades. The molecule has not changed. The packaging has. And the packaging is the problem.
References
AACR. (2025, November 6). AACR expresses support for FDA’s proposed rule to decrease nicotine content in certain combusted tobacco products.
Cato. (2025, September 3). Ban the fear, not the freedom: Massachusetts bill misses the mark on nicotine.
Collateral damage of neonicotinoid insecticides: Unintended effects on gut microbiota of non-target organisms. (2025). Environmental Pollution.
European Commission. (2025, July). Proposal for a Council Directive on the structure and rates of excise duty applied to manufactured tobacco. Tobacco Taxation Directive revision.
European Commission. (2026, May). Call for evidence: Revision of the Tobacco Products Directive. Have Your Say.
European Cancer Organisation. (2026). Response to the European Commission’s call for evidence on the revision of the Tobacco Products Directive.
Even sublethal insecticide dose may disrupt pollinator mating process. (2025, April 21). EurekAlert.
FDA. (2025, January 15). FDA proposes significant step toward reducing nicotine to minimally or nonaddictive level in cigarettes and certain other combusted tobacco products.
Metribolone. (n.d.). In ScienceDirect Topics.
Nicotine-containing products and vaping products. (2025, June 17). Sante Secu.
Nicotine-like effects of the neonicotinoid insecticides acetamiprid and imidacloprid on cerebellar neurons from neonatal rats. (2012). PLoS ONE.
NYT. (1913). Vineyards seek nicotine: Growers use it as an insecticide in the form of a spray. The New York Times.
Pathology of oral nicotine pouches and their addiction mechanisms. (2025). PubMed.
RSPH. (2022, June 1). Nicotine vs caffeine: Which is more harmful? Royal Society for Public Health.
Selective toxicity of neonicotinoids attributable to specificity of insect and mammalian nicotinic receptors. (2002). Annual Review of Entomology.
Simon Chapman. (2019, March 20). As “safe as drinking coffee”? Research spoiling the e-cigarette rehabilitation of nicotine party.
Sub-lethal neonicotinoid exposure impairs homing ability in honey bee (Apis mellifera) foragers via the disruption of energy metabolism and endocrine regulation rather than cognitive ability. (2025). ScienceDirect.
Substance Abuse and Mental Health Services Administration. (n.d.). Co-occurring disorder-related quick facts: Nicotine.
Tobacco Induced Diseases. (2025, June 23). Nicotine replacement therapy for tobacco cessation: Harm reduction or harm re-distribution.
WHO. (2026, May 15). WHO warns nicotine pouch brands targeting youth as sales surge.